Search results
Results from the WOW.Com Content Network
Generally, patients with febrile neutropenia are treated with empirical antibiotics until the neutrophil count has recovered (absolute neutrophil counts greater than 500/mm 3) and the fever has abated; if the neutrophil count does not improve, treatment may need to continue for two weeks or occasionally more. In cases of recurrent or persistent ...
A standardized plan for the management of febrile, neutropenic patients must be devised in each institution or agency., [9] [10] Empirical regimens must contain antibiotics broadly active against Gram-negative aerobic bacteria (a quinolones [i.e. ciprofloxacin, levofloxacin], a fourth-generation cephalosporins [e.g. cefepime, ceftazidime], or ...
Its main uses are in intensive care medicine (pneumonia, peritonitis), some diabetes-related foot infections, and empirical therapy in febrile neutropenia (e.g., after chemotherapy). The drug is administered intravenously every 6 or 8 hr, typically over 3–30 min. It may also be administered by continuous infusion over four hours.
Meropenem, sold under the brand name Merrem among others, is an intravenous carbapenem antibiotic used to treat a variety of bacterial infections. [3] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.
[38] [39] Conditions that indicate the presence of neutropenic fever are implanted devices; leukemia induction; the compromise of mucosal, mucociliary and cutaneous barriers; a rapid decline in absolute neutrophil count, duration of neutropenia >7–10 days, and other illnesses that exist in the patient. [31] Signs of infection can be subtle.
Amikacin is an antibiotic medication used for a number ... for empiric therapy for people with neutropenia and fever. [9] ... by reducing the duration of use. ...
In January 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ryzneuta, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. [2]
Shortly after it was introduced, analyses of whether filgrastim is a cost-effective way of preventing febrile neutropenia depended upon the clinical situation and the financial model used to pay for treatment. [35] The longer-acting pegfilgrastim may in some cases be more cost-effective. [36]